CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, Pang APS, Sugai C, Mahyari E, Francisco EB, Pise A, Rodrigues H, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Bimber BN, Plassmeyer M, Gupta R, Alpan O, O'Halloran JA, Mudd PA, Akalin E, Ndhlovu LC, Sacha JB.
- DOI
- 10.1016/j.ijid.2020.10.101
- Record issued
- 2026-08-03
- Engine
- 7.8.0
- Exported
- 2026-09-03
Prepared by Kaimen Terminal. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at adcurare.com/verify/2938235a-0a9e-4cd1-bd2f-1d6b6e6fc26b is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×3−1.5★
- ClaimsOverstated claim−0.5★
- ReportingStudy design not met−0.5★
- ReportingData & code availability not met−0.5★
- ReportingBiological variables partially met−0.25★
- ReportingEthical approvals partially met−0.25★
- ReportingKey resources partially met−0.25★
- CitationsUnresolved reference−0.25★
- 01Study design lacks key rigor safeguards
The study design is not rigorous; it lacks randomization, blinding, power analysis, explicit inclusion/exclusion criteria, and outlier handling, all of which are not reported.
- 02Data and code not shared
The data availability statement is vague, no data are deposited in a repository, no accession numbers are provided, and custom code is not shared.
“All primary data presented in this study are available from the corresponding author upon reasonable request.”
Data availability - 03Conclusion reaches beyond the evidence
CCR5 blockade represents a novel therapeutic strategy for COVID-19.
“inhibiting the activity of CCL5 via CCR5/RANTES blockade represents a novel therapeutic strategy for COVID-19”
Discussion
This single-arm, open-label study of leronlimab in 10 critically ill COVID-19 patients is exploratory and hypothesis-generating, but it suffers from fundamental design limitations (no randomization, no control, no blinding) and serious reporting gaps (missing informed consent, no data/code sharing, no trial registration). Internal contradictions (n=7 vs n=10 for viremia) and an overstated claim further weaken the paper's robustness.
The evaluation covered all eight rigor dimensions, incorporating three independent reviewer assessments, a copyedit pass, and verification components (statistics, citations, reproducibility, integrity, claim audit). The reviewers diverged on statistical analysis and key resources; the synthesized judgment weighted specific evidence. The study is interventional; no dimensions were deemed not applicable.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.
- CONSISTENTreported p = .001 · recomputed p = <.001Reviewers 1, 2Repeated measures correlation between CD8 percentage and SARS-CoV-2 plasma viral load (n=20, r=-0.77, p=0.0013).How we recomputed it: pR(-0.77, 20)
- lowinternal contradictionRepeated measures correlation reports n=20 observations, but with 7 patients at 3 time points, expected n=21, suggesting missing data not explained.
Plot showing CD8 percentages in blood and SARS-CoV-2 plasma viral load in seven critically ill COVID-19 patients at days 0, 7, and 14 post-leronlimab (n = 20).
Figure 2reviewer’s wording - lowinternal contradictionIn Figure 2F, the left panel shows n=7 for SARS-CoV-2 plasma viral loads, but the text says 'all 10 critically ill patients' received leronlimab.
“SARS-CoV-2 plasma viral loads at days 0, 7, and 14 post-leronlimab (left panel, closed symbols, n = 7).”
Figure 2 - lowinternal contradictionText states all 10 patients had SARS-CoV-2 viremia, but Figure 1E shows n=7 for critical patients in viremia panel.
“SARS-CoV-2 was found in the plasma of all 10 critically ill patients, but no viremia was detected in the healthy controls and in only one patient with mild/moderate COVID-19, thereby highlighting the critical nature of COVID-19 in these patients (E).”
Results ¶4
Overstated conclusions
2 findings · worst mediumConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Conclusions overstated beyond the evidenceAssessed
- Conclusions only partially backed by the presented evidenceAssessed
10 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).
- overstatedReviewer 3CCR5 blockade represents a novel therapeutic strategy for COVID-19.While the data are suggestive, the very small sample size, lack of control, and emergency-use setting prevent strong claims of novelty or therapeutic strategy; the authors acknowledge this by stating 'randomized controlled trials are required'.Evidence: The paper provides preliminary data but no direct evidence of clinical efficacy.
“inhibiting the activity of CCL5 via CCR5/RANTES blockade represents a novel therapeutic strategy for COVID-19”
Discussion - partialReviewers 1, 2CCR5 is a therapeutic target for COVID-19.The data suggest an association between CCR5 blockade and immune restoration, but the small sample size and lack of control limit the strength of this claim. The paper itself acknowledges the need for randomized trials.Evidence: The paper presents immunological and virological data supporting a role for CCR5 in COVID-19 pathology.
“In summary, our results suggest the involvement of CCR5 in the pathology of SARS-CoV-2, and that inhibiting the activity of CCL5 via CCR5/RANTES blockade represents a novel therapeutic strategy for COVID-19 with both immunological and virological implications.”
Discussion - supportedReviewers 1, 2CCR5 blockade via leronlimab reduces inflammatory cytokines in critical COVID-19 patients.The paper shows a statistically significant reduction in plasma IL-6 by day 14, but other cytokines were more variable. The claim is supported for IL-6.Evidence: Figure 2A shows IL-6 levels decrease over time, with p-values from Dunn's Kruskal-Wallis test indicating significance.
“A reduction in the plasma IL-6 was observed as early as 3 days following leronlimab with a return to healthy control levels by day 14 (A).”
Results ¶5 - supportedReviewer 1Leronlimab increases CD8+ T-cell percentages and normalizes CD4/CD8 ratio.Figure 2B and 2C show statistically significant increases in CD8% and normalization of CD4/CD8 ratio over time, supported by p-values.Evidence: Figure 2B and 2C show longitudinal data with p-values.
“Following leronlimab administration, a marked restoration of CD8+ T cells (B) and normalization of the CD4+ and CD8+ T cell ratio were observed in the blood samples (C).”
Results ¶5 - supportedReviewer 1Leronlimab decreases SARS-CoV-2 plasma viral load.Figure 2F shows a decrease in plasma viremia by day 7 and resolution by day 14 in most patients, with a p-value of 0.0012.Evidence: Figure 2F shows individual data points and a p-value from Mann-Whitney test.
“Following leronlimab administration, SARS-CoV-2 plasma viremia decreased in all patients at day 7, and all but one patient had resolved SARS-CoV-2 plasma viremia to undetectable levels by day 14 (F left, p = 0.0012).”
Results ¶7 - supportedReviewer 2Leronlimab increases CD8+ T-cell percentages in blood.The paper reports a marked restoration of CD8+ T cells and normalization of CD4/CD8 ratio, with statistical comparisons.Evidence: Figure 2B shows increase in CD8+ T-cell percentages with p-values.
“Following leronlimab administration, a marked restoration of CD8+ T cells (B) and normalization of the CD4+ and CD8+ T cell ratio were observed in the blood samples (C).”
Figure 2 - supportedReviewer 2Leronlimab decreases SARS-CoV-2 plasma viremia by day 14.The paper shows a decrease in plasma viral load in all patients at day 7 and resolution in all but one by day 14, with a significant p-value.Evidence: Figure 2F shows SARS-CoV-2 plasma viral loads at days 0, 7, and 14, with p=0.0012 from Mann-Whitney test.
“Following leronlimab administration, SARS-CoV-2 plasma viremia decreased in all patients at day 7, and all but one patient had resolved SARS-CoV-2 plasma viremia to undetectable levels by day 14 (F left, p = 0.0012).”
Figure 2 - supportedReviewer 2The increase in CD8 percentage is inversely correlated with the reduction in plasma viral load.The paper reports a statistically significant inverse correlation (r = -0.77, p = 0.0013) using repeated measures correlation.Evidence: Figure 2G shows the correlation with rho and p-value.
“the increase in the CD8 percentage was inversely correlated with the reduction in pVL (r = −0.77, p = 0.0013).”
Figure 2 - supportedReviewer 3CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.The paper presents longitudinal data showing decreases in IL-6, increases in CD8+ T-cells, and resolution of plasma viremia, with statistical tests supporting these changes.Evidence: Figures 2A, 2B, 2C, 2F; reported p-values: Mann-Whitney p=0.0012 for viral load decrease.
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Abstractreviewer’s wording - supportedReviewers 2, 3The results implicate CCR5 as a therapeutic target for COVID-19.The observed immunological and virological changes are consistent with CCR5 blockade, and the discussion appropriately notes this is suggestive.Evidence: Discussion: 'our results suggest the involvement of CCR5 in the pathology of SARS-CoV-2'.
“Our study design precludes clinical efficacy inferences but the results implicate CCR5 as a therapeutic target for COVID-19”
Abstract
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
5 findings · worst highRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data and code not sharedAssessed
- Study design lacks key rigor safeguardsAssessed
- Biological variables underreported (sex, age, strain)Assessed
- Ethics/consent reporting incompleteAssessed
- Key resources under-identified (antibodies, cell lines, RRIDs)Assessed
The introduction cites relevant literature on SARS-CoV-2, cytokine storm, and CCR5, and explicitly states the hypothesis that disrupting the CCL5–CCR5 axis via leronlimab might mitigate immunopathology. Limitations of the study design are acknowledged in the Discussion.
“Given medical triage resulting in patient death and the lack of a placebo control group, we cannot comment on the impact of leronlimab on the clinical outcomes in these patients.”
“we hypothesized that disrupting the CCL5–CCR5 axis via the leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation in COVID-19.”
“Our study design precludes clinical efficacy inferences but the results implicate CCR5 as a therapeutic target for COVID-19”
“we hypothesized that disrupting the CCL5–CCR5 axis via the leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation in COVID-19.”
“It remains unclear why COVID-19 patients experience a spectrum of clinical outcomes ranging from asymptomatic to severe disease”
For a human interventional study, key design elements are missing. No randomization method is described; the study is an open-label single-arm design. Blinding is not mentioned. No a priori power analysis or sample size calculation is provided. Inclusion/exclusion criteria for the leronlimab-treated group are not explicitly stated (only described as 'terminally ill, critical COVID-19 patients'). Outlier handling is not addressed. The control group is observational and not part of the intervention design.
“All leronlimab-treated patients were enrolled in this study under an individual patient emergency use investigation new drug (EIND) via a United States Food and Drug Administration (FDA) emergency use authorization.”
Table 1 lists age and gender for each patient. Health status is described through pre-existing conditions and baseline clinical status. However, weight is not reported, and race/ethnicity is not reported. Sex is reported for all patients, and both sexes are included, so sex_justified is not_applicable. Age and health are reported but weight is missing, making the sub-criterion reported_but_inadequate.
“Table 1 Leronlimab-treated critical COVID-19 patient summaries. Table 1 Day relative to leronlimab | | Patient | Age/Gender |”
The study states that the Albert Einstein College of Medicine IRB and Washington University Saint Louis IRB approved the study. The paper also states compliance with the Helsinki Declaration. However, informed consent from participants is not mentioned, which is a critical omission for human subjects research. The study used emergency use IND, but the paper does not discuss consent or waiver.
“The Albert Einstein College of Medicine Institution Review Board reviewed and approved this study.”
“The study complied with the ethical standards of the Helsinki Declaration.”
“The Albert Einstein College of Medicine Institution Review Board reviewed and approved this study.”
“The study was reviewed and approved by the Washington University Saint Louis Institutional Review Board (WU-350 study approval # 202003085).”
“The Albert Einstein College of Medicine Institution Review Board reviewed and approved this study.”
“The study complied with the ethical standards of the Helsinki Declaration.”
Leronlimab is named and described as a CCR5-specific human IgG4 monoclonal antibody, but no manufacturer, lot number, or formulation details are provided. Antibodies used in flow cytometry are listed by name and fluorophore but without catalog numbers or RRIDs. Kits (e.g., LegendPlex, QIAamp) are identified by vendor. Software (Kaluza, Cellranger, Seurat, etc.) is identified with version numbers. Overall, identification of key resources is incomplete.
“Leronlimab, formerly known as PRO 140, is a CCR5-specific human IgG4 monoclonal antibody in development for HIV therapy as a once weekly, at home subcutaneous injection.”
“anti-CD19 (PE-Dazzle594), anti-CD3 (APC), anti-CD16 (Alexa700), HLA-DR (APC/Fire750), and anti-CTLA-4 (PE-Cy7)”
“Leronlimab, formerly known as PRO 140, is a CCR5-specific human IgG4 monoclonal antibody”
“Analysis was performed with Kaluza version 2.1 software.”
“anti-CD19 (PE-Dazzle594), anti-CD3 (APC), anti-CD16 (Alexa700), HLA-DR (APC/Fire750), and anti-CTLA-4 (PE-Cy7)”
“Analysis was performed with Kaluza version 2.1 software.”
Tests are named (Kruskal-Wallis with Dunn's correction, Mann-Whitney U, Fisher's exact, repeated measures correlation). Exact p-values are reported (e.g., p=0.0013, p=0.0012). The repeated measures correlation includes a 95% confidence interval (−0.93 to 0.35). Software is identified (Kaluza, QuantaSoft, etc.). The absence of explicit assumption verification is mitigated by the use of nonparametric tests. Data presentation is described but individual data points cannot be confirmed from the text; nonetheless, the overall reporting is adequate.
“We performed statistical analyses between groups using the nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison correction to control the experiment-wise error rate.”
“Graph shows rho (ρ) and p - values calculated by repeated measures correlation: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.”
“We performed statistical analyses between groups using the nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison correction to control the experiment-wise error rate.”
“The 95% confidence interval for the repeated measures correlation was −0.93 to 0.35.”
“We performed statistical analyses between groups using the nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison correction to control the experiment-wise error rate. We compared categorical variables using Fisher’s exact test and continuous variables with the Mann–Whitney U test”
The data availability statement says 'All primary data presented in this study are available from the corresponding author upon reasonable request,' which is vague and does not provide a concrete access mechanism. No data are deposited in a public repository, and no accession numbers are given for the scRNA-seq data. Custom code for analysis is not shared. The paper mentions using public 10x Genomics datasets, but those are not the study's own data.
“All primary data presented in this study are available from the corresponding author upon reasonable request.”
“All primary data presented in this study are available from the corresponding author upon reasonable request.”
“All primary data presented in this study are available from the corresponding author upon reasonable request.”
The methods section is comprehensive, covering cytokine assays, flow cytometry, viral load measurement, and scRNA-seq. Limitations are explicitly discussed: 'our study design precludes clinical efficacy inferences' and 'lack of a placebo control group.' Conclusions are cautious, calling for RCTs. Funding and conflicts of interest are declared. However, the study is not registered in a clinical trials registry, and no reporting checklist (e.g., CONSORT) is mentioned. Trial registration is not_reported; reporting guideline is not_reported.
“Given medical triage resulting in patient death and the lack of a placebo control group, we cannot comment on the impact of leronlimab on the clinical outcomes in these patients.”
“In summary, our results suggest the involvement of CCR5 in the pathology of SARS-CoV-2, and that inhibiting the activity of CCL5 via CCR5/RANTES blockade represents a novel therapeutic strategy for COVID-19 with both immunological and virological implications.”
“PBMCs were isolated from peripheral blood using a Lymphoprep density gradient (STEMCELL Technologies, Vancouver, Canada).”
“Given medical triage resulting in patient death and the lack of a placebo control group, we cannot comment on the impact of leronlimab on the clinical outcomes in these patients.”
“Dr. Sacha has received compensation for consulting for CytoDyn Inc., a company that may have a commercial interest in the results of this research.”
“We analyzed changes in clinical presentation, immune cell populations, inflammation, as well as SARS-CoV-2 plasma viremia before and 14 days after treatment.”
“Our study design precludes clinical efficacy inferences but the results implicate CCR5 as a therapeutic target for COVID-19”
“randomized, double blind, placebo controlled clinical trials are underway to assess the efficacy of leronlimab treatments”
Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
1 finding · worst lowReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
- References not resolvable to a published paperRecomputed
Checked 30 references by DOI: 24 verified — 1 DOI unresolved, 5 no DOI (shown, not verified).
- UNRESOLVED10.1016/s1473-471.3099(20)30200-0Clinical and virological data of the first cases of COVID-19 in Europe: a case seriesCited DOI does not resolve to any Crossref record.
- NO DOIFunctional roles of CCL5/RANTES in liver diseaseNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIStudy to Evaluate the Efficacy and Safety of Leronlimab for Mild to ModerateCOVID-19No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIStudy to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICoronavirus Survivor Credits Artificial Antibody Experimental Treatment for RecoveryNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICoronavirus Disease (COVID-2019) Situation ReportsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
2 data/code links checked; 0 live.
- datahttps://support.10xgenomics.com/single-cell-gene-expression/datasetsUNVERIFIEDHTTP 403Liveness indeterminate — content not checked.
- datahttps://support.10xgenomics.com/single-cell-vdj/datasetsUNVERIFIEDHTTP 403Liveness indeterminate — content not checked.
Copyediting
11 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 11 minor suggestions below.
11 copyedit issues flagged: mostly consistency, typo, clarity.
- MINORconsistencyResults, Figure 1E legend“n = 7 in panel e”→ Clarify why only 7 patients had plasma viral load measurements, as the text states all 10 had viremia.The text says 'all 10 critically ill patients' but the figure shows n=7 for viremia.
- MINORclarityMethods, Flow cytometry“anti-CD19 (PE-Dazzle594), anti-CD3 (APC), anti-CD16 (Alexa700), HLA-DR (APC/Fire750), and anti-CTLA-4 (PE-Cy7).”→ Add vendor catalog numbers or RRIDs for each antibody.Lack of catalog numbers reduces reproducibility.
- MINORgrammarAbstract, Results“increases CD8 T-cells”→ Change to 'increases CD8+ T-cell counts' for specificity.Minor phrasing issue.
- MINORtypoMethods, Cytokine assay“Il-4, IL-5, IL-5”→ IL-4, IL-5Duplicate 'IL-5' and inconsistent capitalization of 'Il-4'.
- MINORtypoMethods, Cytokine assay“IL-2 (p40)”→ IL-12 (p40)IL-2 p40 is likely a typo for IL-12 p40, as IL-12 shares p40 subunit.
- MINORconsistencyMethods, Assessment of plasma cytokine and chemokine levels“FNα2”→ IFNα2Inconsistent abbreviation; should be 'IFNα2' for consistency with IFNγ.
- MINORclarityMethods, 10× Genomics 5′ single-cell RNA sequencing“The healthy control reference data were obtained from public 10× genomics data sets”→ Provide full URLs or accession numbers for the public datasets used.The paper lists URLs in the text, but these are generic; specific dataset identifiers would improve reproducibility.
- MINORotherTable 1“TBD”→ Replace with 'Not determined' or specify if still ongoing.TBD appears in several rows but is undefined in the table legend.
- MINORpunctuationResults, paragraph 1“A–C”→ Ensure consistent use of en-dash or em-dash for ranges.Minor formatting inconsistency.
- MINORconsistencyTitle and throughout“SARS-CoV2”→ Change to SARS-CoV-2 for consistency with standard nomenclature.The virus name is typically written with a hyphen.
- MINORtypoAuthor affiliations“IncellDX”→ Change to IncellDx to match company name in the Methods section.Inconsistent capitalization.
This published paper is not robust in its current form. An informed reader should weigh the severe design limitations, the missing informed consent, the internal contradictions in the reported sample sizes, and the absence of data/code sharing. The overstated claim of a 'novel therapeutic strategy' and the unverified reference warrant scrutiny. An erratum or correction is needed to address the internal contradictions and add missing information; independent re-analysis would be ideal but is hindered by the lack of shared data.
- 1.HIGHrigorInvestigate and resolve the internal contradiction: the text states all 10 patients had SARS-CoV-2 viremia, but Figures 1E and 2F show n=7 for viremia measurements. Clarify the discrepancy or correct the figures.This inconsistency undermines the reported data and could indicate a missing data or reporting error that readers must be aware of.
- 2.HIGHrigorInvestigate the repeated measures correlation: reported n=20 observations, but with 7 patients at 3 time points expected n=21. Explain the missing data point or correct the analysis.An unexplained discrepancy in the number of observations raises questions about the integrity of the analysis.
- 3.HIGHreportingAdd a statement on informed consent: report whether informed consent was obtained from the leronlimab-treated patients or, if waived under EIND, provide the justification and approval details.Missing informed consent is a critical ethical reporting gap that must be addressed in an erratum.
- 4.HIGHdata codeDeposit the scRNA-seq and other primary data in a public repository (e.g., GEO, Zenodo) with accession numbers, and replace the vague data availability statement with a concrete link.Without data deposit, the study cannot be independently verified or re-analyzed, which is a major reproducibility concern.
- 5.HIGHreportingTemper the claim that 'CCR5 blockade represents a novel therapeutic strategy for COVID-19' to reflect the exploratory nature of the study, given the small sample, lack of control, and emergency-use setting.The claim is overstated given the study's limitations; an erratum should adjust the language to match the evidence.
- 6.HIGHotherVerify the reference with DOI 10.1016/s1473-471.3099(20)30200-0 (title: 'Clinical and virological data of the first cases of COVID-19 in Europe: a case series') which was not found in Crossref/OpenAlex. Correct the DOI or remove the citation if it cannot be verified.An unresolved reference may be fabricated; correcting it is essential for citation integrity.
- 7.HIGHreportingRegister the study in a clinical trials registry (e.g., ClinicalTrials.gov) and report the registration number, or explicitly state why registration was not obtained (e.g., emergency use).Trial registration is standard for interventional studies and its absence reduces transparency.
- 8.HIGHreportingReference a reporting guideline such as CONSORT (for non-randomized trials) in the Methods section, or explain why it was not followed.Adherence to reporting guidelines improves completeness and reproducibility.
- 9.HIGHstatisticsIdentify the statistical software used for the main analyses (e.g., GraphPad Prism, R version) in the Statistical analysis section.Missing software identification hinders reproducibility of the analyses.
- 10.MEDIUMstatisticsReport effect sizes and confidence intervals for all group comparisons (e.g., Cohen's d for Mann-Whitney tests), not only the repeated measures correlation.Effect sizes allow readers to assess the magnitude of differences, which is critical for interpretation.
- 11.MEDIUMstatisticsDefine error bars in all figure legends (e.g., SD, SEM, or CI).Undefined error bars make it impossible to interpret the variability in the data.
- 12.MEDIUMreportingAdd weight and race/ethnicity to Table 1 or a supplementary table.These demographic variables are important for assessing generalizability and potential confounding.
- 13.MEDIUMreportingProvide catalog numbers or RRIDs for all antibodies and key reagents (e.g., leronlimab lot number) in the Methods or a supplementary file.Missing resource identifiers reduces reproducibility of the experimental protocols.
- 14.MEDIUMcopyeditCorrect the typo in Methods, Cytokine assay: 'IL-2 (p40)' should be 'IL-12 (p40)', and 'Il-4' should be 'IL-4'. Also fix the duplicate 'IL-5'.These typos could cause confusion about which cytokines were measured.
- 15.MEDIUMcopyeditStandardize the virus name to 'SARS-CoV-2' (with hyphen) throughout the manuscript.Consistency with standard nomenclature improves readability and professionalism.
- 16.LOWcopyeditReplace 'TBD' in Table 1 with 'Not determined' or specify the actual value if available.Undefined abbreviations in tables can confuse readers.
- 17.LOWcopyeditAdd full URLs or dataset identifiers for the public 10x Genomics datasets referenced in the Methods.Providing specific identifiers improves reproducibility of the bioinformatics analysis.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Kaimen Rigor grades the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolates the paper’s major claims and checks its own evidence backs them, and flags integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.
This Kaimen Rigor review uses Kaimen Rigor trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.